Amarin Corp Plcuk (AMRN) Tax Provisions (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Tax Provisions of $1.8 million for Q1 2026, down 13.45% year-over-year from $2.1 million in Q1 2025, and up 380.91% quarter-over-quarter from $372000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Tax Provisions (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 14 years of Tax Provisions data on file, last reported at $1.8 million in Q1 2026.
- Tax Provisions for Q1 2026 came in at $1.8 million, down 13.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (down 57.01% YoY), and the FY2025 annual result was $2.8 million, down 44.81% from the prior year.
- Tax Provisions climbed to $1.8 million in Q1 2026 per AMRN's latest filing, from $372000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $5.2 million in Q2 2022 and troughed at -$7.6 million in Q4 2022.
- A 5-year average of $997882.4 and a median of $1.3 million in 2024 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2022 and 2024: Tax Provisions sank 550.09% in 2022, then surged 619.56% in 2024.
- A 5-year view of Tax Provisions shows it stood at -$7.6 million in 2022, then jumped by 143.68% to $3.3 million in 2023, then plunged by 138.69% to -$1.3 million in 2024, then surged by 128.86% to $372000.0 in 2025, then jumped by 380.91% to $1.8 million in 2026.
- Business Quant data shows AMRN's Tax Provisions at $1.8 million in Q1 2026, $372000.0 in Q4 2025, and -$377000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -411.19 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.45 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 755.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 342.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 709.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 265.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 559.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 461.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 561.00 Mn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 1.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.79 Mn |
| Dec 31, 2025 | 372,000.00 |
| Sep 30, 2025 | -377,000.00 |
| Jun 30, 2025 | 689,000.00 |
| Mar 31, 2025 | 2.07 Mn |
| Dec 31, 2024 | -1.29 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 3.33 Mn |
| Sep 30, 2023 | 501,000.00 |
| Jun 30, 2023 | -355,000.00 |
| Mar 31, 2023 | 1.96 Mn |
| Dec 31, 2022 | -7.63 Mn |
| Sep 30, 2022 | 1.26 Mn |
| Jun 30, 2022 | 5.16 Mn |
| Mar 31, 2022 | 3.21 Mn |
| Dec 31, 2021 | 1.70 Mn |
| Sep 30, 2021 | 184,000.00 |
| Jun 30, 2021 | 1.06 Mn |